Ascletis announces that its clinical trial application for the oral PD-L1 small molecule inhibitor ASC61 for the treatment of advanced solid tumors has been approved by the China National Food
Time of Update: 2023-01-01
Ascletis Pharmaceuticals Limited (HKEx: 1672, "Ascletis") today announced that ASC61, an oral small molecule inhibitor of oral PD-L1, has been approved by the National Medical Products Administration (NMPA) of China (NMPA) for a New Drug Clinical Trial (IND) application for the treatment of advanced solid tumors.
Shanghai Chengsi Protective Mask Air Tightness Tester Technical exchange and experience
Time of Update: 2022-10-03
Protective mask airtightness tester respirator as a respiratory protection equipment required in the field of medical protection, the type of mask can be mainly divided into disposable masks, replacea
Local innovative drug companies join forces to actively explore clinical value
Time of Update: 2022-09-30
In China, the drug has completed two Phase III clinical studies of duodenal ulcer and gastroesophageal reflux, and submitted a marketing application for 2 indications to the State Food and Drug Administration in September 2021, and is currently undergoing review and approval.
Yangtze River's big move
Time of Update: 2021-11-05
Currently, 15 innovative drugs (14 are category 1 new drugs) are in the clinical application and above stage; 79 have been reviewed The varieties (22 are the first ones) are eye-catching, helping the company to harvest a lot in centralized procurement; 76 new classifications are under review, and 20 have not been approved for the first copy .
The Market Supervision Department of Ningxia Hui Autonomous Region strengthens the random inspection and testing of illegal addition of non-edible substances in catering food
Time of Update: 2021-11-01
Supervise food production, catering, special rectification, food safety supervision, illegal addition of non-edible substances, hot pot sampling inspection, food seasoning inspection Up to now, 194 batches of sampling and testing have been completed , including 64 batches of hot pot seasonings and 130 batches of soups, with a pass rate of 100%, and no illegal additions have been found .
Tengshengbo Pharmaceutical submitted an emergency use authorization application for the new crown neutralizing antibody to the FDA, which has better efficacy than small molecule drugs
Time of Update: 2021-10-22
Currently, the new crown neutralizing antibody BRII-196/BRII-198 "cocktail" therapy is undergoing phase 3 clinical trials in multiple centers around the world .
Hengrui Medicine's 3 new drugs approved for clinical treatment of diabetes and tumors
Time of Update: 2021-09-05
According to the latest announcement by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, Hengrui Medicine's three new biological drugs have recently obtained
Tianyan announced the third clinical trial cooperation with Merck
Time of Update: 2021-08-26
On August 19th, Tianyan Pharmaceutical (NASDAQ: ADAG) announced that it had reached a third clinical trial cooperation agreement with Merck & Co.
The two parties will initiate an open-label, dose escalation and extended study clinical trial (ADG106-P2001/KEYNOTE- D12) to evaluate the clinical efficacy of the combination in patients with advanced or metastatic solid and/or hematological malignancies .
Biotech, which is hitting the three-inch recharge, will be cleaned up
Time of Update: 2021-08-08
Text | CloverLast Friday, CDE's notice of opinions on the "Clinical Value-Oriented Anti-tumor Drug Clinical Research and Development Guidelines" (hereinafter referred to as the "Guiding Principles") triggered a "big shock" and heated discussions in the pharmaceutical industry .
The first class 1 new drug
Time of Update: 2021-07-31
Text | plus oneOn July 24, the CDE official website showed that Qilu Pharmaceutical submitted and accepted a listing application for a new class 1 drug "Yiluok Tablets" .
Immunity: "harmful" fat may inhibit the body's ability to attack cancer cells by killer T cells
Time of Update: 2021-06-22
Recently, in a research report titled "Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors" published in the international journal Immunity , scientists from Salk Institute and other institutions Studies have found that the tumor microenvironment contains a large number of oxidized lipid molecules.
New Drug Development: Anti-HER3 Targeted Therapy 30 Years of Creeping Road
Time of Update: 2021-04-27
The pan-HER family inhibitor Sym013 is a mixture of six humanized full-length monoclonal antibodies against three targets of EGFR, HER2, and HER3, and has been shown to reduce the growth of cancer cells in vivo and in vitro.
JCC: Analysis of the effectiveness and safety of Ustekinumab in ulcerative colitis
Time of Update: 2021-04-22
. Figure: Changes in the efficacy of Ulsinumumab in the treatment of ulcerative colitis This study confirms that Ustekinumab has a good effect on alleviating disease activity in real life, both in the short and long term, but a higher burden of inflammation at baseline is associated with a lower probability of remission.
The application for clinical trial of the MCLA-129 injectable drug from Beda Pharmaceuticals was accepted
Time of Update: 2021-01-24
As of the date of disclosure of this announcement, Johnson and Johnson's EGFR/c-Met dual-specific antibody Amivantamab filed a Biological Product Licensing Application (BLA) and Marketing Authorization Application (MAA) with the FDA and the European EMA in December 2020, respectively, for the treatment of metastasis non-small cell lung cancer patients with EGFR exon 20 insertion mutations.
Rongchang Bioc-Met Targets ADC for the first time in China to be approved clinically
Time of Update: 2021-01-19
Insight data show that most of the c-MET targeted drugs currently under study in China are small molecule drugs, and only 4 antibody drugs are currently in clinical stage, namely, Xi'an Jansen's EGFR/c-Met dual anti-Amivantamab, AbbVie's ADC drug ABBV-399, Hengrui's ADC drug injection with SHR-A1403, and Upper Coast's EGFR/c-Met dual anti-EMB-01 injection.